Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
About this trial
This is an interventional diagnostic trial for Kidney Cancer focused on measuring Kidney Cancer, Renal Mass, Open partial nephrectomy, Ultrasound-guided surgery, DEFINITY, Contrast agent, Phone call
Eligibility Criteria
Inclusion Criteria:
- Patients must have previous cross sectional imaging (CT or MRI) demonstrating renal mass or masses that is amenable to open partial nephrectomy.
- Patient is scheduled for intraoperative ultrasound guided open partial nephrectomy.
- Patient must sign informed consent, with risks and benefits of CEUS explained (see risks outlined on the following pages)
Exclusion Criteria:
- Patients with known renal mass scheduled for total or laparoscopic partial nephrectomy.
- Patients who are hypersensitive to Definity (Perflutren Lipid Microsphere)
- Patients with known history of right-to-left, bidirectional or transient right-to-left cardiac shunts.
- Pediatric patients less than 18 years of age.
- Pregnant or nursing mothers.
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Experimental
Contrast Enhanced Intraoperative Ultrasound
During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent. Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier. Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.